Drugs / IMOVAX Polio
IMOVAX Polio
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01997632 | Nov 2013 → May 2014 | poliomyelitis | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT00885157 | Apr → Oct 2009 | poliomyelitis | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT03169725 | May 2017 → Jan 2019 | poliomyelitis | LG Chem | Completed | Met primary |
| Phase 43 trials | ||||||
| Phase 4 | NCT02005536 | Dec 2013 → Sep 2014 | poliomyelitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT01278433 | Dec 2010 → Dec 2011 | poliomyelitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT01244464 | Nov 2010 → Jun 2011 | poliomyelitis | Sanofi | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT00604058 Comparator | Jan → Sep 2008 | poliomyelitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00290342 Comparator | Jan 2006 → Jan 2007 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMOVAX Polio | “Commercialized IPV based on Salk strain (Imovax Polio). Should be injected by intramuscular three injections in the anterolateral aspect of thigh at 6, 10 and 14 weeks of age.” NCT03169725 ↗7“fractional doses of sanofi pasteur's IMOVAX Polio injected intradermally” NCT00604058 ↗ “sanofi pasteur's IMOVAX Polio injected intradermally” NCT00885157 ↗ |
| Known as | IMOVAX Polio (IPV) vaccine | “IMOVAX Polio (IPV) vaccine” NCT00604058 ↗ |
| Known as | SP059 | “The aim of the study is to assess the immunogenicity of SP059 (IMOVAX POLIO®: Inactive Poliovirus Vaccine) vaccine against poliovirus and safety after fifth dose.” NCT02005536 ↗ |
| Modality | Vaccine | “Sanofi-Pasteur's IMOVAX Polio® (IPV) vaccine” NCT00290342 ↗ |
| Route | Intramuscular | “0.5 mL, Intramuscular” NCT01278433 ↗ |